
News|Articles|March 1, 2003
ANDROMEDA study of dronedarone ends due to potential excess risk of death
Sanofi-Synthélabo has decided to discontinue ANDROMEDA under advisementfrom its steering committee and the independent Data Safety and MonitoringBoard (DSMB) for the study, the company announced recently. ANDROMEDA wasa double-blind, placebo-controlled study in the process of evaluating theuse of dronedarone in high-risk patients with congestive heart failure andventricular dysfunction. A total of 627 of the intended 1,000 patients hadalready been enrolled in the study.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Advancing Equity and Access in Breast Cancer Care
2
Aflibercept 8 mg Shows Promise in Reducing Injection Burden | AAO 2025
3
Type 1 Diabetes Drug Tzield Under Expedited Review Through New FDA Program
4
Final Takeaways of the GALAXI-2 and GALAXI-3 Trials From Lead Investigators
5